177 related articles for article (PubMed ID: 15888284)
1. Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.
Yamaguchi K; Nakamura M; Shirahane K; Konomi H; Torata N; Hamasaki N; Kawakita M; Tanaka M
Dig Liver Dis; 2005 Mar; 37(3):190-4. PubMed ID: 15888284
[TBL] [Abstract][Full Text] [Related]
2. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M
Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
[TBL] [Abstract][Full Text] [Related]
3. [Urine diacetylspermine as a novel tumor marker].
Yamaguchi K; Kaku T; Enjoji M; Kato M; Anai M; Kawakita M; Hamasaki N; Tanaka M
Rinsho Byori; 2005 Feb; 53(2):130-5. PubMed ID: 15796046
[TBL] [Abstract][Full Text] [Related]
4. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers.
Umemori Y; Ohe Y; Kuribayashi K; Tsuji N; Nishidate T; Kameshima H; Hirata K; Watanabe N
Clin Chim Acta; 2010 Dec; 411(23-24):1894-9. PubMed ID: 20655890
[TBL] [Abstract][Full Text] [Related]
7. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
8. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
10. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
[TBL] [Abstract][Full Text] [Related]
11. Determination of N¹,N¹²-diacetylspermine in urine: a novel tumor marker.
Kawakita M; Hiramatsu K; Yanagiya M; Doi Y; Kosaka M
Methods Mol Biol; 2011; 720():367-78. PubMed ID: 21318886
[TBL] [Abstract][Full Text] [Related]
12. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
13. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
15. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
[TBL] [Abstract][Full Text] [Related]
17. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of IGF-I and IGFBP-III and their relation with carcinoembryonic antigen and carbohydrate antigen 19-9 in cases of esophageal cancer.
Yilmaz O; Eroglu A; Dag E; Karaoglanoglu N; Yilmaz A
Int J Clin Pract; 2006 Dec; 60(12):1604-8. PubMed ID: 16704680
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]